Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een onderzoek ter evaluatie van de veiligheid en farmacokinetiek van AZD7760 bij gezonde volwassenen (fase I) en volwassenen met nierziekte in het eindstadium die hemodialyse ondergaan met een centrale veneuze katheter (fase IIa) (PEAK)

27 oktober 2026 bijgewerkt door: AstraZeneca

Een fase I/IIa gerandomiseerde, dubbelblinde, placebogecontroleerde studie om de veiligheid en farmacokinetiek van AZD7760 te evalueren bij gezonde deelnemers en bij patiënten met nierziekte in het eindstadium die hemodialyse ondergaan via een centrale veneuze katheter

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).

Studie Overzicht

Toestand

Actief, niet wervend

Gedetailleerde beschrijving

In the Phase I portion of the study, participants will be randomized to receive one of 3 dosages of AZD7760 or placebo as a single intravenous infusion.

Study details include:

  • A 28-day Screening Period.
  • A Dosing Period of 3 days in which a single intravenous infusion will be given on Day 1.
  • A Follow-up Period of 12 months from the time of administration of the study intervention.

In the Phase IIa portion of the study, participants will be randomized to receive either AZD7760 or placebo as 2 intravenous infusions given 3 months apart.

Study details include:

  • A 28-day Screening Period.
  • A Dosing Period in which 2 intravenous infusions will be given 3 months apart (Day 1 and Day 91).
  • A Follow-up Period of 12 months after the last administration of the study intervention on Day 91.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

242

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Alabama
      • Huntsville, Alabama, Verenigde Staten, 35805
        • Research Site
    • California
      • Chula Vista, California, Verenigde Staten, 91910
        • Research Site
      • Glendale, California, Verenigde Staten, 91206
        • Research Site
      • Granada Hills, California, Verenigde Staten, 91344
        • Research Site
      • Los Angeles, California, Verenigde Staten, 90027
        • Research Site
      • Northridge, California, Verenigde Staten, 91324
        • Research Site
      • Northridge, California, Verenigde Staten, 91325
        • Research Site
      • Oxnard, California, Verenigde Staten, 93036
        • Research Site
      • Riverside, California, Verenigde Staten, 92503
        • Research Site
      • San Dimas, California, Verenigde Staten, 91773
        • Research Site
      • Tarzana, California, Verenigde Staten, 91356
        • Research Site
      • Valencia, California, Verenigde Staten, 91355
        • Research Site
      • Victorville, California, Verenigde Staten, 92392
        • Research Site
    • Colorado
      • Englewood, Colorado, Verenigde Staten, 80110
        • Research Site
    • Florida
      • Bradenton, Florida, Verenigde Staten, 34209
        • Research Site
      • Coral Springs, Florida, Verenigde Staten, 33071
        • Research Site
      • Hollywood, Florida, Verenigde Staten, 33024
        • Research Site
      • Orlando, Florida, Verenigde Staten, 32806
        • Research Site
      • Tampa, Florida, Verenigde Staten, 33603
        • Research Site
    • Georgia
      • Lawrenceville, Georgia, Verenigde Staten, 30046
        • Research Site
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60640
        • Research Site
      • Chicago, Illinois, Verenigde Staten, 60643
        • Research Site
    • Iowa
      • Iowa City, Iowa, Verenigde Staten, 52242
        • Research Site
    • Kentucky
      • Lexington, Kentucky, Verenigde Staten, 40503
        • Research Site
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21225
        • Research Site
    • Michigan
      • Detroit, Michigan, Verenigde Staten, 48202
        • Research Site
      • Pontiac, Michigan, Verenigde Staten, 48341
        • Research Site
    • Mississippi
      • Tupelo, Mississippi, Verenigde Staten, 38801
        • Research Site
    • Missouri
      • Kansas City, Missouri, Verenigde Staten, 64111
        • Research Site
    • Nebraska
      • Lincoln, Nebraska, Verenigde Staten, 68510
        • Research Site
    • Nevada
      • Las Vegas, Nevada, Verenigde Staten, 89128
        • Research Site
    • New Jersey
      • Jersey City, New Jersey, Verenigde Staten, 07305
        • Research Site
    • New Mexico
      • Albuquerque, New Mexico, Verenigde Staten, 87109
        • Research Site
    • New York
      • Ridgewood, New York, Verenigde Staten, 11385
        • Research Site
    • North Carolina
      • Winston-Salem, North Carolina, Verenigde Staten, 27103
        • Research Site
    • Pennsylvania
      • Bethlehem, Pennsylvania, Verenigde Staten, 18017
        • Research Site
    • Texas
      • Beaumont, Texas, Verenigde Staten, 77706
        • Research Site
      • Dallas, Texas, Verenigde Staten, 75246
        • Research Site
      • Houston, Texas, Verenigde Staten, 77074
        • Research Site
      • McAllen, Texas, Verenigde Staten, 78503
        • Research Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 55 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Phase I:

  • Participant must be 18 to 55 years of age (inclusive), at the time of signing the informed consent.
  • Body weight ≥ 45 kilograms (kg) and ≤ 110 kg and Body Mass Index (BMI) within the range ≥ 18.0 to ≤ 30.0 kilograms per square meter (kg/m2) (inclusive) at screening.
  • Healthy participants with no clinically significant concomitant diseases or medications (except for those specifically permitted by the protocol) according to medical history, physical examination, screening safety laboratory tests, and screening parameters, as per the judgement of the investigator.

Phase IIa:

  • Participant must be ≥ 18 years of age at the time of signing the informed consent.

  • Participants who meet all of the following disease status requirements:

    1. Diagnosed with End-stage kidney disease (ESKD).
    2. Requiring hemodialysis through a tunneled central venous catheter as the primary vascular access for hemodialysis.
    3. Receiving hemodialysis for treatment of ESKD for at least 60 days before randomization.
    4. At least 3 previous dialysis sessions using current dialyzer.
    5. Receiving adequate hemodialysis based on a single-pool Kt/V measurement > 1.2 within the last 30 days.
    6. No new medications have been added to the participant's regimen in the last 2 weeks prior to dosing. 'New medication' is defined as any medication that has not been prescribed or used by the participant previously (including formulation changes). Medication previously prescribed or used by the participant with dose adjustments is allowed and not considered as new medication for the purpose of this study.
    7. Not taking long-term systemic antibiotics with activity against S aureus.

Exclusion Criteria:

Phase I:

  • Known hypersensitivity to any component of the study intervention
  • Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of monoclonal antibodies (mAbs).
  • Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.
  • Aspartate Aminotransferase (AST) or alanine Aminotransferase (ALT) above 1.5 × upper limit of normal (ULN) at screening. Testing may be repeated once at the investigator's discretion.
  • Estimated glomerular filtration rate < 90 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation at screening.
  • Hemoglobin or platelet count below the lower limit of normal at screening. Testing may be repeated once at the investigator's discretion.
  • White blood cell counts outside normal reference ranges unless judged by the investigator to be out of range given the known variation in white blood cell count reference interval by ethnicity. Testing may be repeated once at the investigator's discretion.
  • History of malignancy other than treated non-melanoma skin cancers or locally treated cervical cancer in the previous 5 years.
  • Any laboratory value in the screening panel that, in the opinion of the investigator, is clinically significant or might confound analysis of study results. Testing may be repeated once at the investigator's discretion.
  • Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) at screening, as judged by the investigator.
  • Acute (time-limited) illness, including fever ≥ 38 °C (100.4 °F), one day prior to or on day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves within the 28-day Screening Period or may be rescreened once.
  • Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening.
  • Any condition that has the potential to increase clearance of the study intervention (eg, protein loss conditions such as severe enteropathies, or plasmapheresis).
  • Blood drawn in excess of a total of 450 milliliters (mL) (1 unit) for any reason within 2 months prior to screening.
  • Absence of suitable veins for blood sampling and administration of study intervention.
  • Any other condition that would compromise safety of the participants.
  • Any condition that, in the opinion of the investigator, might interfere with evaluation of the study intervention or interpretation of participant safety or study results.

Phase IIa:

  • Known hypersensitivity to any component of the study intervention.

  • History of allergic disease or reactions likely to be exacerbated by any component of the study intervention as listed in dose formulation section.

  • Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of mAbs.

  • Hemoglobin < 9 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.

  • Serum albumin of < 3 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.

  • Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (eg, deep vein thrombosis or pulmonary embolism, but excluding vascular access thrombosis) within 90 days prior to randomization.

  • Known S aureus infection within 90 days of study entry.

  • Known acute viral or bacterial infection or symptoms/signs consistent with such an infection within the 21 days prior to infusion or study intervention. Mild intercurrent viral illness with a temperature of 38.1 °C (100.6 °F) or less does not require exclusion, if in the judgement of the investigator this illness will not interfere with the evaluation of the mAb.

  • Participants with malignancy undergoing chemotherapy.

  • Scheduled date for living donor kidney transplant.

  • Plans to switch to peritoneal dialysis within the primary endpoint time period (181 days).

  • Regarding arteriovenous fistula (AVF) or arteriovenous graft (AVG):

    (a) Future AVG or AVG: (i) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG use within 90 days of randomization are not eligible.

(ii) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG placement, but no plans for AVF or AVG use within 90 days of randomization are eligible.

(b) Existing AVG or AVG: (i) Participants with central venous catheters in use for dialysis, but also with an existing AVF or AVG that is not in use and with no future plans for use are eligible.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Phase I: AZD7760 Dose A

Participants will receive a single dose of AZD7760 Dose A intravenously on Day 1.

Participants will receive AZD7760 as a single intravenous infusion.

Experimenteel: Phase I: AZD7760 Dose B

Participants will receive a single dose of AZD7760 Dose B intravenously on Day 1.

Participants will receive AZD7760 as a single intravenous infusion.

Experimenteel: Phase I: AZD7760 Dose C

Participants will receive a single dose of AZD7760 Dose C intravenously on Day 1.

Participants will receive AZD7760 as a single intravenous infusion.

Placebo-vergelijker: Phase I: Placebo

Participants will receive a single dose of placebo on Day 1.

Participants will be administered placebo through intravenous infusion.

Experimenteel: Phase IIa: AZD7760 Dose D and Placebo

Participants will receive AZD7760 Dose D and placebo on Day 1 on Day 91.

Participants will receive AZD7760 as a single intravenous infusion.

Participants will be administered placebo through intravenous infusion.

Experimenteel: Phase IIa: AZD7760 Dose E

Participants will receive AZD7760 Dose E on Day 1 and Day 91.

Participants will receive AZD7760 as a single intravenous infusion.

Placebo-vergelijker: Phase IIa: Placebo

Participants will receive placebo on Day 1 and on Day 91.

Participants will be administered placebo through intravenous infusion.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase I: Occurence of adverse events (AEs)
Tijdsspanne: Day 1 to Day 181

To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C.

Day 1 to Day 181
Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)
Tijdsspanne: Day 1 to Day 361

To evaluate the safety of AZD7760 administered as a single IV Dose A, B, or C.

Day 1 to Day 361
Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIs
Tijdsspanne: Day 1 to Day 181

To evaluate the safety of AZD7760 compared with placebo as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase I: Maximum observed plasma (peak) drug concentration (Cmax)
Tijdsspanne: Day 1 to Day 361

To characterize the pharmacokinetics (PK) of AZD7760 in serum.

Day 1 to Day 361
Phase I: Time to reach peak or maximum observed concentration following drug administration (tmax)
Tijdsspanne: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)
Tijdsspanne: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)
Tijdsspanne: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf)
Tijdsspanne: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Apparent volume of distribution at steady state (Vss)
Tijdsspanne: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Apparent volume of distribution at the terminal phase (Vz)
Tijdsspanne: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Incidence of ADA
Tijdsspanne: Day 1 to Day 361

To evaluate ADA responses to AZD7760 in serum.

Day 1 to Day 361
Phase IIa: Cmax
Tijdsspanne: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: tmax
Tijdsspanne: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: t1/2λz
Tijdsspanne: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: AUClast
Tijdsspanne: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: AUCinf
Tijdsspanne: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Vss
Tijdsspanne: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Vz
Tijdsspanne: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Incidence of anti-drug antibodies (ADAs) to AZD7760 in serum
Tijdsspanne: Day 1 to Day 181 and Day 1 to Day 451

To evaluate ADA responses to AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Occurrence of AEs
Tijdsspanne: Day 1 to Day 181

To evaluate the safety to Day 181 of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181
Phase IIa: Occurrence of MAAEs, SAEs, and AESIs
Tijdsspanne: Day 1 to Day 451

To evaluate the safety to Day 451 of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 451

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

30 december 2024

Primaire voltooiing (Geschat)

8 maart 2027

Studie voltooiing (Geschat)

13 december 2027

Studieregistratiedata

Eerst ingediend

23 december 2024

Eerst ingediend dat voldeed aan de QC-criteria

23 december 2024

Eerst geplaatst (Werkelijk)

27 december 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

27 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD-tijdsbestek voor delen

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-toegangscriteria voor delen

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren